logo-loader
viewCB2 Insights

Full interview: CB2 Insights licenses electronic data capture software to UK firm MYACCESS Clinics

CB2 Insights (CSE:CBII-OTCQB: CBIIF) CEO Prad Sekar joined Steve Darling from Proactive Vancouver to discuss the company doing a deal with MYACCESS Clinics. This will allow CB2’s software to capture comprehensive data sets related to patient health and treatment histories and manage ongoing medical cannabis treatment outcome data. 

Sekar talks about what this partnership means for CB2 moving forward.

Quick facts: CB2 Insights

Price: 0.09 CAD

CSE:CBII
Market: CSE
Market Cap: $7.09 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights named herein, including the promotion by the Company of CB2 Insights in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Buds & Duds: Cannabis stocks in the green; CB2 Insights gets boost from...

Buds today are CB2 Insights (CSE:CBII) (OTCQB:CBIIF), Cannvas MedTech Inc (CSE:MTEC) (OTCMKTS:CANVF). Duds are Canopy Growth Corp (TSE:WEED) (NYSE:CGC), Choom (CSE:CHOO) (OTCMKTS:CHOOF).

on 07/31/2019

2 min read